Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance
<p<Abstract</p< <p<Background</p< <p<Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceuti...
Ausführliche Beschreibung
Autor*in: |
Heise Michael [verfasserIn] Lautem Anja [verfasserIn] Knapstein Johanna [verfasserIn] Schattenberg Jörn M [verfasserIn] Hoppe-Lotichius Maria [verfasserIn] Foltys Daniel [verfasserIn] Weiler Nina [verfasserIn] Zimmermann Anca [verfasserIn] Schad Arno [verfasserIn] Gründemann Dirk [verfasserIn] Otto Gerd [verfasserIn] Galle Peter R [verfasserIn] Schuchmann Marcus [verfasserIn] Zimmermann Tim [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2012 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: BMC Cancer - BMC, 2003, 12(2012), 1, p 109 |
---|---|
Übergeordnetes Werk: |
volume:12 ; year:2012 ; number:1, p 109 |
Links: |
---|
DOI / URN: |
10.1186/1471-2407-12-109 |
---|
Katalog-ID: |
DOAJ065042972 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ065042972 | ||
003 | DE-627 | ||
005 | 20230309044050.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2012 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/1471-2407-12-109 |2 doi | |
035 | |a (DE-627)DOAJ065042972 | ||
035 | |a (DE-599)DOAJ17dd77f852344e59b97de0af5de3dea8 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC254-282 | |
100 | 0 | |a Heise Michael |e verfasserin |4 aut | |
245 | 1 | 0 | |a Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance |
264 | 1 | |c 2012 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a <p<Abstract</p< <p<Background</p< <p<Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).</p< <p<Methods</p< <p<OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs.</p< <p<Results</p< <p<Real time PCR showed a downregulation of <it<SLC22A1 </it<and <it<SLC22A3 </it<in HCC compared to TST (p ≤ 0.001). A low <it<SLC22A1 </it<expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, <it<SLC22A1 </it<was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low <it<SLC22A1 </it<expression (< median) showed a higher <it<SLC22A3 </it<expression compared to HCC with high <it<SLC22A1 </it<expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the <it<SLC22A3 </it<expression.</p< <p<In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.</p< <p<Conclusion</p< <p<The downregulation of OCT1 is associated with tumor progression and a worse patient survival.</p< | ||
650 | 4 | |a OCT1 | |
650 | 4 | |a OCT3 | |
650 | 4 | |a SLC22A1 | |
650 | 4 | |a SLC22A3 | |
650 | 4 | |a Hepatocellular carcinoma | |
650 | 4 | |a HCC | |
653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
700 | 0 | |a Lautem Anja |e verfasserin |4 aut | |
700 | 0 | |a Knapstein Johanna |e verfasserin |4 aut | |
700 | 0 | |a Schattenberg Jörn M |e verfasserin |4 aut | |
700 | 0 | |a Hoppe-Lotichius Maria |e verfasserin |4 aut | |
700 | 0 | |a Foltys Daniel |e verfasserin |4 aut | |
700 | 0 | |a Weiler Nina |e verfasserin |4 aut | |
700 | 0 | |a Zimmermann Anca |e verfasserin |4 aut | |
700 | 0 | |a Schad Arno |e verfasserin |4 aut | |
700 | 0 | |a Gründemann Dirk |e verfasserin |4 aut | |
700 | 0 | |a Otto Gerd |e verfasserin |4 aut | |
700 | 0 | |a Galle Peter R |e verfasserin |4 aut | |
700 | 0 | |a Schuchmann Marcus |e verfasserin |4 aut | |
700 | 0 | |a Zimmermann Tim |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t BMC Cancer |d BMC, 2003 |g 12(2012), 1, p 109 |w (DE-627)326643710 |w (DE-600)2041352-X |x 14712407 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2012 |g number:1, p 109 |
856 | 4 | 0 | |u https://doi.org/10.1186/1471-2407-12-109 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/17dd77f852344e59b97de0af5de3dea8 |z kostenfrei |
856 | 4 | 0 | |u http://www.biomedcentral.com/1471-2407/12/109 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1471-2407 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 12 |j 2012 |e 1, p 109 |
author_variant |
h m hm l a la k j kj s j m sjm h l m hlm f d fd w n wn z a za s a sa g d gd o g og g p r gpr s m sm z t zt |
---|---|
matchkey_str |
article:14712407:2012----::oneuainfraictotasotrotisc21tnotisc23tnuahptcluacr |
hierarchy_sort_str |
2012 |
callnumber-subject-code |
RC |
publishDate |
2012 |
allfields |
10.1186/1471-2407-12-109 doi (DE-627)DOAJ065042972 (DE-599)DOAJ17dd77f852344e59b97de0af5de3dea8 DE-627 ger DE-627 rakwb eng RC254-282 Heise Michael verfasserin aut Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).</p< <p<Methods</p< <p<OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs.</p< <p<Results</p< <p<Real time PCR showed a downregulation of <it<SLC22A1 </it<and <it<SLC22A3 </it<in HCC compared to TST (p ≤ 0.001). A low <it<SLC22A1 </it<expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, <it<SLC22A1 </it<was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low <it<SLC22A1 </it<expression (< median) showed a higher <it<SLC22A3 </it<expression compared to HCC with high <it<SLC22A1 </it<expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the <it<SLC22A3 </it<expression.</p< <p<In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.</p< <p<Conclusion</p< <p<The downregulation of OCT1 is associated with tumor progression and a worse patient survival.</p< OCT1 OCT3 SLC22A1 SLC22A3 Hepatocellular carcinoma HCC Neoplasms. Tumors. Oncology. Including cancer and carcinogens Lautem Anja verfasserin aut Knapstein Johanna verfasserin aut Schattenberg Jörn M verfasserin aut Hoppe-Lotichius Maria verfasserin aut Foltys Daniel verfasserin aut Weiler Nina verfasserin aut Zimmermann Anca verfasserin aut Schad Arno verfasserin aut Gründemann Dirk verfasserin aut Otto Gerd verfasserin aut Galle Peter R verfasserin aut Schuchmann Marcus verfasserin aut Zimmermann Tim verfasserin aut In BMC Cancer BMC, 2003 12(2012), 1, p 109 (DE-627)326643710 (DE-600)2041352-X 14712407 nnns volume:12 year:2012 number:1, p 109 https://doi.org/10.1186/1471-2407-12-109 kostenfrei https://doaj.org/article/17dd77f852344e59b97de0af5de3dea8 kostenfrei http://www.biomedcentral.com/1471-2407/12/109 kostenfrei https://doaj.org/toc/1471-2407 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2012 1, p 109 |
spelling |
10.1186/1471-2407-12-109 doi (DE-627)DOAJ065042972 (DE-599)DOAJ17dd77f852344e59b97de0af5de3dea8 DE-627 ger DE-627 rakwb eng RC254-282 Heise Michael verfasserin aut Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).</p< <p<Methods</p< <p<OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs.</p< <p<Results</p< <p<Real time PCR showed a downregulation of <it<SLC22A1 </it<and <it<SLC22A3 </it<in HCC compared to TST (p ≤ 0.001). A low <it<SLC22A1 </it<expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, <it<SLC22A1 </it<was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low <it<SLC22A1 </it<expression (< median) showed a higher <it<SLC22A3 </it<expression compared to HCC with high <it<SLC22A1 </it<expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the <it<SLC22A3 </it<expression.</p< <p<In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.</p< <p<Conclusion</p< <p<The downregulation of OCT1 is associated with tumor progression and a worse patient survival.</p< OCT1 OCT3 SLC22A1 SLC22A3 Hepatocellular carcinoma HCC Neoplasms. Tumors. Oncology. Including cancer and carcinogens Lautem Anja verfasserin aut Knapstein Johanna verfasserin aut Schattenberg Jörn M verfasserin aut Hoppe-Lotichius Maria verfasserin aut Foltys Daniel verfasserin aut Weiler Nina verfasserin aut Zimmermann Anca verfasserin aut Schad Arno verfasserin aut Gründemann Dirk verfasserin aut Otto Gerd verfasserin aut Galle Peter R verfasserin aut Schuchmann Marcus verfasserin aut Zimmermann Tim verfasserin aut In BMC Cancer BMC, 2003 12(2012), 1, p 109 (DE-627)326643710 (DE-600)2041352-X 14712407 nnns volume:12 year:2012 number:1, p 109 https://doi.org/10.1186/1471-2407-12-109 kostenfrei https://doaj.org/article/17dd77f852344e59b97de0af5de3dea8 kostenfrei http://www.biomedcentral.com/1471-2407/12/109 kostenfrei https://doaj.org/toc/1471-2407 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2012 1, p 109 |
allfields_unstemmed |
10.1186/1471-2407-12-109 doi (DE-627)DOAJ065042972 (DE-599)DOAJ17dd77f852344e59b97de0af5de3dea8 DE-627 ger DE-627 rakwb eng RC254-282 Heise Michael verfasserin aut Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).</p< <p<Methods</p< <p<OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs.</p< <p<Results</p< <p<Real time PCR showed a downregulation of <it<SLC22A1 </it<and <it<SLC22A3 </it<in HCC compared to TST (p ≤ 0.001). A low <it<SLC22A1 </it<expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, <it<SLC22A1 </it<was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low <it<SLC22A1 </it<expression (< median) showed a higher <it<SLC22A3 </it<expression compared to HCC with high <it<SLC22A1 </it<expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the <it<SLC22A3 </it<expression.</p< <p<In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.</p< <p<Conclusion</p< <p<The downregulation of OCT1 is associated with tumor progression and a worse patient survival.</p< OCT1 OCT3 SLC22A1 SLC22A3 Hepatocellular carcinoma HCC Neoplasms. Tumors. Oncology. Including cancer and carcinogens Lautem Anja verfasserin aut Knapstein Johanna verfasserin aut Schattenberg Jörn M verfasserin aut Hoppe-Lotichius Maria verfasserin aut Foltys Daniel verfasserin aut Weiler Nina verfasserin aut Zimmermann Anca verfasserin aut Schad Arno verfasserin aut Gründemann Dirk verfasserin aut Otto Gerd verfasserin aut Galle Peter R verfasserin aut Schuchmann Marcus verfasserin aut Zimmermann Tim verfasserin aut In BMC Cancer BMC, 2003 12(2012), 1, p 109 (DE-627)326643710 (DE-600)2041352-X 14712407 nnns volume:12 year:2012 number:1, p 109 https://doi.org/10.1186/1471-2407-12-109 kostenfrei https://doaj.org/article/17dd77f852344e59b97de0af5de3dea8 kostenfrei http://www.biomedcentral.com/1471-2407/12/109 kostenfrei https://doaj.org/toc/1471-2407 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2012 1, p 109 |
allfieldsGer |
10.1186/1471-2407-12-109 doi (DE-627)DOAJ065042972 (DE-599)DOAJ17dd77f852344e59b97de0af5de3dea8 DE-627 ger DE-627 rakwb eng RC254-282 Heise Michael verfasserin aut Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).</p< <p<Methods</p< <p<OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs.</p< <p<Results</p< <p<Real time PCR showed a downregulation of <it<SLC22A1 </it<and <it<SLC22A3 </it<in HCC compared to TST (p ≤ 0.001). A low <it<SLC22A1 </it<expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, <it<SLC22A1 </it<was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low <it<SLC22A1 </it<expression (< median) showed a higher <it<SLC22A3 </it<expression compared to HCC with high <it<SLC22A1 </it<expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the <it<SLC22A3 </it<expression.</p< <p<In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.</p< <p<Conclusion</p< <p<The downregulation of OCT1 is associated with tumor progression and a worse patient survival.</p< OCT1 OCT3 SLC22A1 SLC22A3 Hepatocellular carcinoma HCC Neoplasms. Tumors. Oncology. Including cancer and carcinogens Lautem Anja verfasserin aut Knapstein Johanna verfasserin aut Schattenberg Jörn M verfasserin aut Hoppe-Lotichius Maria verfasserin aut Foltys Daniel verfasserin aut Weiler Nina verfasserin aut Zimmermann Anca verfasserin aut Schad Arno verfasserin aut Gründemann Dirk verfasserin aut Otto Gerd verfasserin aut Galle Peter R verfasserin aut Schuchmann Marcus verfasserin aut Zimmermann Tim verfasserin aut In BMC Cancer BMC, 2003 12(2012), 1, p 109 (DE-627)326643710 (DE-600)2041352-X 14712407 nnns volume:12 year:2012 number:1, p 109 https://doi.org/10.1186/1471-2407-12-109 kostenfrei https://doaj.org/article/17dd77f852344e59b97de0af5de3dea8 kostenfrei http://www.biomedcentral.com/1471-2407/12/109 kostenfrei https://doaj.org/toc/1471-2407 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2012 1, p 109 |
allfieldsSound |
10.1186/1471-2407-12-109 doi (DE-627)DOAJ065042972 (DE-599)DOAJ17dd77f852344e59b97de0af5de3dea8 DE-627 ger DE-627 rakwb eng RC254-282 Heise Michael verfasserin aut Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).</p< <p<Methods</p< <p<OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs.</p< <p<Results</p< <p<Real time PCR showed a downregulation of <it<SLC22A1 </it<and <it<SLC22A3 </it<in HCC compared to TST (p ≤ 0.001). A low <it<SLC22A1 </it<expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, <it<SLC22A1 </it<was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low <it<SLC22A1 </it<expression (< median) showed a higher <it<SLC22A3 </it<expression compared to HCC with high <it<SLC22A1 </it<expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the <it<SLC22A3 </it<expression.</p< <p<In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.</p< <p<Conclusion</p< <p<The downregulation of OCT1 is associated with tumor progression and a worse patient survival.</p< OCT1 OCT3 SLC22A1 SLC22A3 Hepatocellular carcinoma HCC Neoplasms. Tumors. Oncology. Including cancer and carcinogens Lautem Anja verfasserin aut Knapstein Johanna verfasserin aut Schattenberg Jörn M verfasserin aut Hoppe-Lotichius Maria verfasserin aut Foltys Daniel verfasserin aut Weiler Nina verfasserin aut Zimmermann Anca verfasserin aut Schad Arno verfasserin aut Gründemann Dirk verfasserin aut Otto Gerd verfasserin aut Galle Peter R verfasserin aut Schuchmann Marcus verfasserin aut Zimmermann Tim verfasserin aut In BMC Cancer BMC, 2003 12(2012), 1, p 109 (DE-627)326643710 (DE-600)2041352-X 14712407 nnns volume:12 year:2012 number:1, p 109 https://doi.org/10.1186/1471-2407-12-109 kostenfrei https://doaj.org/article/17dd77f852344e59b97de0af5de3dea8 kostenfrei http://www.biomedcentral.com/1471-2407/12/109 kostenfrei https://doaj.org/toc/1471-2407 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2012 1, p 109 |
language |
English |
source |
In BMC Cancer 12(2012), 1, p 109 volume:12 year:2012 number:1, p 109 |
sourceStr |
In BMC Cancer 12(2012), 1, p 109 volume:12 year:2012 number:1, p 109 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
OCT1 OCT3 SLC22A1 SLC22A3 Hepatocellular carcinoma HCC Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
isfreeaccess_bool |
true |
container_title |
BMC Cancer |
authorswithroles_txt_mv |
Heise Michael @@aut@@ Lautem Anja @@aut@@ Knapstein Johanna @@aut@@ Schattenberg Jörn M @@aut@@ Hoppe-Lotichius Maria @@aut@@ Foltys Daniel @@aut@@ Weiler Nina @@aut@@ Zimmermann Anca @@aut@@ Schad Arno @@aut@@ Gründemann Dirk @@aut@@ Otto Gerd @@aut@@ Galle Peter R @@aut@@ Schuchmann Marcus @@aut@@ Zimmermann Tim @@aut@@ |
publishDateDaySort_date |
2012-01-01T00:00:00Z |
hierarchy_top_id |
326643710 |
id |
DOAJ065042972 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ065042972</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309044050.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2012 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1471-2407-12-109</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ065042972</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ17dd77f852344e59b97de0af5de3dea8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Heise Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).</p< <p<Methods</p< <p<OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs.</p< <p<Results</p< <p<Real time PCR showed a downregulation of <it<SLC22A1 </it<and <it<SLC22A3 </it<in HCC compared to TST (p ≤ 0.001). A low <it<SLC22A1 </it<expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, <it<SLC22A1 </it<was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low <it<SLC22A1 </it<expression (< median) showed a higher <it<SLC22A3 </it<expression compared to HCC with high <it<SLC22A1 </it<expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the <it<SLC22A3 </it<expression.</p< <p<In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.</p< <p<Conclusion</p< <p<The downregulation of OCT1 is associated with tumor progression and a worse patient survival.</p<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">OCT1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">OCT3</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SLC22A1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SLC22A3</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatocellular carcinoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HCC</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lautem Anja</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Knapstein Johanna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schattenberg Jörn M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hoppe-Lotichius Maria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Foltys Daniel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Weiler Nina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zimmermann Anca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schad Arno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gründemann Dirk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Otto Gerd</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Galle Peter R</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schuchmann Marcus</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zimmermann Tim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">BMC Cancer</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">12(2012), 1, p 109</subfield><subfield code="w">(DE-627)326643710</subfield><subfield code="w">(DE-600)2041352-X</subfield><subfield code="x">14712407</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:1, p 109</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1471-2407-12-109</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/17dd77f852344e59b97de0af5de3dea8</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.biomedcentral.com/1471-2407/12/109</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1471-2407</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2012</subfield><subfield code="e">1, p 109</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Heise Michael |
spellingShingle |
Heise Michael misc RC254-282 misc OCT1 misc OCT3 misc SLC22A1 misc SLC22A3 misc Hepatocellular carcinoma misc HCC misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance |
authorStr |
Heise Michael |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)326643710 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC254-282 |
illustrated |
Not Illustrated |
issn |
14712407 |
topic_title |
RC254-282 Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance OCT1 OCT3 SLC22A1 SLC22A3 Hepatocellular carcinoma HCC |
topic |
misc RC254-282 misc OCT1 misc OCT3 misc SLC22A1 misc SLC22A3 misc Hepatocellular carcinoma misc HCC misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
topic_unstemmed |
misc RC254-282 misc OCT1 misc OCT3 misc SLC22A1 misc SLC22A3 misc Hepatocellular carcinoma misc HCC misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
topic_browse |
misc RC254-282 misc OCT1 misc OCT3 misc SLC22A1 misc SLC22A3 misc Hepatocellular carcinoma misc HCC misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
BMC Cancer |
hierarchy_parent_id |
326643710 |
hierarchy_top_title |
BMC Cancer |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)326643710 (DE-600)2041352-X |
title |
Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance |
ctrlnum |
(DE-627)DOAJ065042972 (DE-599)DOAJ17dd77f852344e59b97de0af5de3dea8 |
title_full |
Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance |
author_sort |
Heise Michael |
journal |
BMC Cancer |
journalStr |
BMC Cancer |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2012 |
contenttype_str_mv |
txt |
author_browse |
Heise Michael Lautem Anja Knapstein Johanna Schattenberg Jörn M Hoppe-Lotichius Maria Foltys Daniel Weiler Nina Zimmermann Anca Schad Arno Gründemann Dirk Otto Gerd Galle Peter R Schuchmann Marcus Zimmermann Tim |
container_volume |
12 |
class |
RC254-282 |
format_se |
Elektronische Aufsätze |
author-letter |
Heise Michael |
doi_str_mv |
10.1186/1471-2407-12-109 |
author2-role |
verfasserin |
title_sort |
downregulation of organic cation transporters oct1 (<it<slc22a1</it<) and oct3 (<it<slc22a3</it<) in human hepatocellular carcinoma and their prognostic significance |
callnumber |
RC254-282 |
title_auth |
Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance |
abstract |
<p<Abstract</p< <p<Background</p< <p<Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).</p< <p<Methods</p< <p<OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs.</p< <p<Results</p< <p<Real time PCR showed a downregulation of <it<SLC22A1 </it<and <it<SLC22A3 </it<in HCC compared to TST (p ≤ 0.001). A low <it<SLC22A1 </it<expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, <it<SLC22A1 </it<was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low <it<SLC22A1 </it<expression (< median) showed a higher <it<SLC22A3 </it<expression compared to HCC with high <it<SLC22A1 </it<expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the <it<SLC22A3 </it<expression.</p< <p<In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.</p< <p<Conclusion</p< <p<The downregulation of OCT1 is associated with tumor progression and a worse patient survival.</p< |
abstractGer |
<p<Abstract</p< <p<Background</p< <p<Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).</p< <p<Methods</p< <p<OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs.</p< <p<Results</p< <p<Real time PCR showed a downregulation of <it<SLC22A1 </it<and <it<SLC22A3 </it<in HCC compared to TST (p ≤ 0.001). A low <it<SLC22A1 </it<expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, <it<SLC22A1 </it<was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low <it<SLC22A1 </it<expression (< median) showed a higher <it<SLC22A3 </it<expression compared to HCC with high <it<SLC22A1 </it<expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the <it<SLC22A3 </it<expression.</p< <p<In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.</p< <p<Conclusion</p< <p<The downregulation of OCT1 is associated with tumor progression and a worse patient survival.</p< |
abstract_unstemmed |
<p<Abstract</p< <p<Background</p< <p<Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).</p< <p<Methods</p< <p<OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs.</p< <p<Results</p< <p<Real time PCR showed a downregulation of <it<SLC22A1 </it<and <it<SLC22A3 </it<in HCC compared to TST (p ≤ 0.001). A low <it<SLC22A1 </it<expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, <it<SLC22A1 </it<was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low <it<SLC22A1 </it<expression (< median) showed a higher <it<SLC22A3 </it<expression compared to HCC with high <it<SLC22A1 </it<expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the <it<SLC22A3 </it<expression.</p< <p<In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.</p< <p<Conclusion</p< <p<The downregulation of OCT1 is associated with tumor progression and a worse patient survival.</p< |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
1, p 109 |
title_short |
Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance |
url |
https://doi.org/10.1186/1471-2407-12-109 https://doaj.org/article/17dd77f852344e59b97de0af5de3dea8 http://www.biomedcentral.com/1471-2407/12/109 https://doaj.org/toc/1471-2407 |
remote_bool |
true |
author2 |
Lautem Anja Knapstein Johanna Schattenberg Jörn M Hoppe-Lotichius Maria Foltys Daniel Weiler Nina Zimmermann Anca Schad Arno Gründemann Dirk Otto Gerd Galle Peter R Schuchmann Marcus Zimmermann Tim |
author2Str |
Lautem Anja Knapstein Johanna Schattenberg Jörn M Hoppe-Lotichius Maria Foltys Daniel Weiler Nina Zimmermann Anca Schad Arno Gründemann Dirk Otto Gerd Galle Peter R Schuchmann Marcus Zimmermann Tim |
ppnlink |
326643710 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1186/1471-2407-12-109 |
callnumber-a |
RC254-282 |
up_date |
2024-07-04T01:17:03.815Z |
_version_ |
1803609255514734593 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ065042972</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309044050.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2012 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1471-2407-12-109</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ065042972</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ17dd77f852344e59b97de0af5de3dea8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Heise Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Downregulation of organic cation transporters OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) in human hepatocellular carcinoma and their prognostic significance</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).</p< <p<Methods</p< <p<OCT1 (<it<SLC22A1</it<) and OCT3 (<it<SLC22A3</it<) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs.</p< <p<Results</p< <p<Real time PCR showed a downregulation of <it<SLC22A1 </it<and <it<SLC22A3 </it<in HCC compared to TST (p ≤ 0.001). A low <it<SLC22A1 </it<expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, <it<SLC22A1 </it<was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low <it<SLC22A1 </it<expression (< median) showed a higher <it<SLC22A3 </it<expression compared to HCC with high <it<SLC22A1 </it<expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the <it<SLC22A3 </it<expression.</p< <p<In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.</p< <p<Conclusion</p< <p<The downregulation of OCT1 is associated with tumor progression and a worse patient survival.</p<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">OCT1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">OCT3</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SLC22A1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SLC22A3</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatocellular carcinoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HCC</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lautem Anja</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Knapstein Johanna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schattenberg Jörn M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hoppe-Lotichius Maria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Foltys Daniel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Weiler Nina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zimmermann Anca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schad Arno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gründemann Dirk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Otto Gerd</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Galle Peter R</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schuchmann Marcus</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zimmermann Tim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">BMC Cancer</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">12(2012), 1, p 109</subfield><subfield code="w">(DE-627)326643710</subfield><subfield code="w">(DE-600)2041352-X</subfield><subfield code="x">14712407</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:1, p 109</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1471-2407-12-109</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/17dd77f852344e59b97de0af5de3dea8</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.biomedcentral.com/1471-2407/12/109</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1471-2407</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2012</subfield><subfield code="e">1, p 109</subfield></datafield></record></collection>
|
score |
7.4003963 |